Cohere didn’t buy a product. It bought a research team with deep-domain biomedical expertise and a Berlin footprint, and it’s the company’s second acquisition with German ties in a matter of weeks.
Reliant AI, founded in 2023 and headquartered across Montreal and Berlin, raised $11.3 million in seed funding from Inovia Capital and Tola Capital before Cohere confirmed the deal on May 19. The acquisition target is “North for Pharma”, Cohere’s new agentic AI system designed specifically for the highly regulated global biopharma and life sciences market. Karl Moritz Hermann, formerly of Google DeepMind, joins Cohere as VP of AI Verticalizations. Marc G. Bellemare joins as VP of Modelling, described by the company as a CIFAR AI Chair at Mila. No purchase price was disclosed, and coverage across betakit.com, AFP, and hpcwire.com confirms that no financial terms appear in any of the reporting.
The real story is the pattern, not the deal. This is Cohere’s second acquisition with German roots in a short window, following its previously announced merger with Aleph Alpha, reportedly targeting a combined trans-Atlantic valuation of approximately $20 billion, according to prior reports. Two deals. Two German ties. Both aimed at regulated markets where sovereign AI isn’t a feature, it’s a procurement requirement.
Analysis
This is Cohere's second acquisition with German roots in weeks. Both targets, Aleph Alpha and now Reliant AI, serve regulated markets where sovereign AI is a procurement requirement, not a differentiator. The verticalization into biopharma with a named product ('North for Pharma') marks a shift from platform-level to industry-level positioning.
Why does that matter? Enterprise buyers in pharma, financial services, and regulated healthcare don’t just want capable AI. They need AI that can operate inside their data perimeter, meet jurisdiction- specific compliance requirements, and document its reasoning for audit purposes. Cohere’s trans-Atlantic consolidation strategy is positioning the platform to be that answer for European and global regulated enterprises. Reliant AI’s biopharma specialization makes life sciences the chosen beachhead vertical, a sector with some of the highest AI compliance burdens globally.
This is also the third significant enterprise AI acquisition with a European connection in recent pipeline cycles, following Mistral’s Emmi AI deal and Anthropic’s Stainless acquisition on May 19. Cohere’s move is different in structure, though: it’s not acquiring capability to bolt onto a general platform. It’s verticalizing, building a named product, North for Pharma, that signals to biopharma procurement teams that this is a purpose-built system, not an adapted one.
What to Watch
What to watch
whether North for Pharma generates a named customer announcement within the next quarter. Cohere hasn’t disclosed revenue or customer counts for its enterprise vertical products. A major pharma or life sciences reference customer would confirm whether the verticalization thesis is converting to commercial traction. Watch also for any integration announcements that clarify how Reliant AI’s research capabilities are being absorbed, and whether the Berlin presence is being maintained or consolidated.
TJS synthesis
Cohere is assembling a sovereign AI stack through targeted acquisitions rather than organic capability build. The pattern is now two data points: German-connected targets, regulated industries, undisclosed terms. Enterprise buyers in pharma evaluating AI platforms should treat this as a signal that Cohere’s roadmap is being shaped by compliance-first verticals, which either makes it a stronger fit or narrows its general-purpose appeal, depending on what you’re buying. Watch for a named North for Pharma customer at the next Cohere earnings or product event.